Abstract: The invention provides a new human growth regulator protein (GRREG) and polynucleotides which identify and encode GRREG. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of GRREG.
Type:
Grant
Filed:
July 11, 1997
Date of Patent:
June 27, 2000
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Olga Bandman, Preeti Lal, Purvi Shah, Neil C. Corley
Abstract: The invention provides a human glutaredoxin .beta. (GRX.beta.) and polynucleotides which identify and encode GRX.beta.. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of GRX.beta..
Type:
Grant
Filed:
August 14, 1997
Date of Patent:
October 19, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Jennifer L. Hillman, Neil C. Corley, Purvi Shah
Abstract: The invention provides a human maternally transcribed protein (HMTP) and polynucleotides which identify and encode HMTP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HMTP.
Type:
Grant
Filed:
October 3, 1997
Date of Patent:
October 12, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Jennifer L. Hillman, Preeti Lal, Neil C. Corley
Abstract: The invention provides a new human integral membrane protein (NIMPH) and polynucleotides which identify and encode NIMPH. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of NIMPH.
Abstract: The invention provides a human aflatoxin B1 aldehyde reductase (AFB1-hAR) and polynucleotides which identify and encode AFB1-hAR. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of AFB1-hAR.
Type:
Grant
Filed:
August 8, 1997
Date of Patent:
July 6, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Olga Bandman, Purvi Shah, Karl J. Guegler, Neil C. Corley
Abstract: The present invention provides a human MAGE-like protein (MAGELP) and polynucleotides which identify and encode MAGELP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding MAGELP and a method for producing MAGELP. The invention also provides for agonists, antibodies, or antagonists specifically binding MAGELP, and their use, in the prevention and treatment of diseases associated with expression of MAGELP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding MAGELP for the treatment of diseases associated with the expression of MAGELP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding MAGELP.
Abstract: The invention provides a human insulin receptor tyrosine kinase substrate (IRS-p53h) and polynucleotides which identify and encode IRS-p53h. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of IRS-p53h.
Type:
Grant
Filed:
June 19, 1997
Date of Patent:
April 6, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Jennifer L. Hillman, Preeti Lal, Purvi Shah
Abstract: The invention provides human disease associated protein kinases and polynucleotides (collectively designated DAPK) which identify and encode them. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention further provides methods for diagnosing and treating disorders associated with expression of human disease associated protein kinases.
Type:
Grant
Filed:
June 19, 1997
Date of Patent:
March 23, 1999
Assignee:
Incyte Pharmaceuticals, Inc.
Inventors:
Olga Bandman, Jennifer L. Hillman, Neil C. Corley, Karl J. Guegler, Preeti Lal, Surya K. Goli, Purvi Shah
Abstract: The present invention provides two regulators of G-protein signaling (designated individually as RGPS-1 and RGPS-2, and collectively as RGPS) and polynucleotides which identify and encode RGPS. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention also provides methods for producing RGPS and for treating or preventing disorders associated with expression of RGPS.